The PSCI is delighted to be an Official Sustainability Partner for CPHI Milan, the biggest international pharma industry event.

We'll be exhibiting throughout the conference in Milan from 6-8 October, and attending the inaugural CPHI Sustainability Summit on Monday 5 October.

The PSCI stand H47 will be located in Hall 16, where we will be showcasing the impact that the PSCI has through the pharmaceutical supply chain.

Meet with us on-site
Please contact the Secretariat if you are planning to attend and would like to arrange a meeting.

CPHI & PMEC China brings together suppliers and buyers across the entire pharma supply chain, in the home of modern medicine. Position your business as a key player in a thriving market and access a market built on rapid innovation. Join us in Shanghai to network, source cost-effective solutions, and conduct vital face-to-face business.

PSCI Members will be speaking at the event. For more information, check out the agenda.

The packaging sector is facing a wave of overlapping and rapidly evolving EU regulatory requirements that affect businesses across the entire supply chain - from manufacturers and importers through to distributors and online platforms. This webinar will provide practical guidance on the key obligations and deadlines that companies need to prepare for now, with a particular focus on the chemicals sector.

Key topics to be covered:

• The PPWR at a glance:
  an overview and key milestones on the compliance timeline.
• Who bears responsibility:
  defining the various types of economic operators within the supply chain manufacturer, importer, distributor, fulfilment provider - and understanding the distinction.
• PFAS restrictions in packaging:
  from 12 August 2026, food-contact packaging must not be placed on the market where PFAS are present at or above specified concentration thresholds, with a broader universal PFAS restriction under REACH currently under SEAC/RAC evaluation, with a draft opinion consultation planned for spring 2026.
• REACH and PPWR - a dual compliance framework:
  the PPWR recognises that substances in packaging and packaging components are primarily addressed under REACH, yet Article 5 PPWR adds a parallel, independent obligation binding from 12 August 2026, requiring that the presence and concentration of substances of concern in packaging be minimised.
• Microplastics - where REACH Entry 78 and the PPWR interact:
  Entry 78 of Annex XVII REACH (introduced by Regulation (EU) 2023/2055) restricts Synthetic Polymer Microparticles (SPM) – how does this interact with PPWR.
• EPR obligations and enforcement:
  Member States have until 12 February 2027 to adopt penalties, with no specific enforcement guidance yet issued.
• Practical next steps for companies:
  Product reformulation, supply chain due diligence and supplier compliance verification, contractual safeguards, and monitoring the Commission's forthcoming delegated acts.

Speakers:

• Claudio Mereu, Partner, Bird & Bird (Brussels)
• Natalie Konings, Partner, Bird & Bird (Brussels)

Japan is Asia’s engine for advanced drug discovery, a global leader in innovation, quality, and regulatory excellence. As the world’s third-largest pharma market, it’s home to groundbreaking R&D, high production standards, and unmatched trust in healthcare.

CPHI Japan connects you to this thriving ecosystem, giving you access to the companies, insights, and opportunities shaping the future of pharmaceuticals across Asia Pacific.

In the modern chemical and pharmaceutical landscape, reactive chemical hazards represent one of the most significant risks to process safety and business continuity. Undetected thermal instabilities or improperly sized relief systems can lead to catastrophic runaway reactions, resulting in loss of life, environmental damage, and total asset loss. This intensive two-day workshop, led by industry experts from Kaypear in collaboration with the PSCI, provides a comprehensive roadmap for identifying, quantifying, and mitigating reactive risks.

Registration Process
If you are interested in attending this workshop, please register your interest below. Registration does not guarantee a place. Your attendance will be confirmed in due course. Please note that attendance is limited to one person per organization.

Who should attend
As this is a core technical topic, professionals with the following qualifications and job roles are requested to register:

• Process safety engineers/Chemical engineers in technology transfer, technical services, R&D, and process engineers with operations / technical back ground of more than 5 years is recommended.
• Engineers in senior management involved in technical reviews

Day 1

• 08:30-09:00: Registration, Networking, and Tea-Coffee
• 09:00-09:15: PSCI India Connect Overview
• 09:15-09:25: Context Setting / PSCI Audit Findings
• 09:25-09:30: Speaker Introduction
• 09:30-11:00: What reactive hazards are and why they matter with case studies: Examples of reactive hazard scenarios & Common types of reactive chemicals based on functional groups, chemical incompatibility, and thermal stability
• 11:00-11: 15:Tea Break/Net working
• 11:15-13:00: Testing and hazard evaluation using calorimetry (DSC, TGA, ARC, TMRad, ARSST, RC1, RC2, etc.)
  • Testing protocol and methods available
  • Limitation, advantage, and disadvantage of each type of calorimeter
  • Data interpretation of the thermal stability reports
• 13:00-14:00: Lunch/Networking
• 14:00-15:30: Development, calculation, and impact of heat of reaction, reaction rate, and TMRad with a workshop example
• 15:30-15:45: High Tea/Networking
• 15:45-17:00: Stossel’s Criticality Index, CCPS Probability vs Severity table - Sharing case studies - Optimization to safer criticality classes
• 17:00-17:30: Day 1 Summary & Q&A

Day 2

• 08:30-09:00: Registrations/Networking/Tea-Coffee
• 09:00-09:15: Recap & Quiz
• 09:15-11:15: Introduction to DIERS methodology and direct scale up
  • Test protocol for vent sizing using a workshop problem
  • Emergency Relief System (ERS) training for vent sizing using direct scale up
  • Scale up of high phi factor vs direct scale up
• 11:15-11:30: Tea Break/Networking
• 11:30-13:00: Credibility of external fire induced runaway reaction - Sizing for external fire scenario
• 13:00-14:00: Lunch/Networking
• 14:00-15:45: How to control reactive hazards, including:
  • Mode of operation depending on the reaction rate (Batch, Semi-Batch, Continuous)
  • Understanding the effect of temperature of no return (TNR)
  • Likelihood scale based on TMRad
  • Quench calculations and reaction termination chemicals
  • Vent sizing using direct scale up
  • Introduction of Modern DRIERS tools
• 15:45-16:00: High Tea/Networking
• 16:00-16:30: SRV/RD testing + frequency
  Type testing - Flow verification - Field observations + common issues
• 16:30-17:00: Workshop Summary & Q&A

Speakers

Mr. Rahul Raman
Rahul Raman is Principal Engineer and Subject Matter Expert at Kaypear with over 19 years of global expertise in process safety management (PSM) across the United States, Mexico, China, South Korea, and India. A Chartered Chemical Engineer with a Master's degree from Carnegie Mellon University and a B.Tech in Chemical Engineering from Anna University, he specializes in emergency relief system design, technical process safety, and process safety management implementation. Rahul has successfully led major projects in oil and gas, petrochemical, and chemical industries, including relief system gap assessments, HAZOP studies, quantitative risk assessments, and implementing process safety standards.

Mr. Pramod Mekhya
Mr. Pramodbhai Mekhya is a seasoned Chemical Engineer and Process Safety Specialist with over 19 years of industrial experience spanning process development, process safety, scale-up, and advanced calorimetry techniques in the pharmaceutical and chemical industries.
He has extensive hands-on expertise in thermal hazard assessment, reaction calorimetry, adiabatic calorimetry, and process scale-up, supporting both R&D laboratories and manufacturing plants to design safer and more efficient chemical processes. He brings a rare combination of industrial manufacturing experience and advanced safety instrumentation expertise, enabling participants to gain practical insights into reaction hazard evaluation, calorimetry data interpretation, and safe process scale-up strategies.

PSCI Chair Rob Williams, Senior Director of Sustainable Procurement at AstraZeneca, will be speaking at ethica26 – the Human Rights in Supply Chains Leadership Summit, taking place in London on 17 March 2026.

Rob will share practical insight into how procurement leaders can move beyond policies and audits to embed human rights into everyday sourcing decisions, strengthening accountability, resilience, and supplier partnerships across global supply chains.

ethica26 brings together senior leaders from procurement, sustainability, legal, and investment functions to explore what effective, credible action on forced labour and human rights looks like in practice.

PSCI Members are encouraged to join the conversation and connect with peers facing similar challenges across complex supply chains.

PSCI Member 20% discount available: PSCI26

Learn more here: ethica26: Human Rights in Supply Chains Leadership Summit, London

The Energize program aims to increase access to renewable electricity for suppliers in the pharmaceutical industry. The program is growing and now has 26 global pharmaceutical companies working to support their suppliers to decarbonize and mitigate the overall environmental impact of the industry. Join Schneider Electric, Energize program manager, to learn more about the program and benefits of participating.

Agenda
What is Energize?
Why is Energize important?
Program Education
Renewable Electricity Procurement Support
Program Benefits
What to expect when you join the program and next steps

Choose your session
Wednesday 11 February
Thursday 12 February

About Energize
The Energize program is a supply chain renewables initiative designed and delivered by Schneider Electric Sustainability Business and endorsed by the PSCI.

Current Energize sponsors: Almirall, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Charles River Laboratories, Chiesi Group, GSK, Haleon, Johnson & Johnson, Kenvue, Merck (known as MSD outside the United States and Canada), Merck KGaA, Darmstadt, Germany, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Schott, Takeda, Teva, UHG, and UCB.